About
Oncology and hematology therapeutics, Bispecific Antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodySeattle/Pacific Northwest
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
489
By Phase
PHASE1: 7PHASE1/PHASE2: 2
By Status
COMPLETED: 4RECRUITING: 2TERMINATED: 2WITHDRAWN: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT04973618Lead Sponsor
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
PHASE1Withdrawn
Started: Jan 31, 2025 · Completed: Jan 31, 2027
NCT06634394Lead Sponsor
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
PHASE1Recruiting
39 participants
Started: Oct 1, 2024 · Completed: Mar 31, 2028
NCT05934539Lead Sponsor
ALG.APV-527 First-in-human Study
PHASE1/PHASE2Recruiting
56 participants
Started: Dec 23, 2022 · Completed: Dec 1, 2025
NCT03768219Lead Sponsor
Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
PHASE1Terminated
85 participants
Started: Mar 18, 2019 · Completed: Jun 30, 2020
NCT02262910Lead Sponsor
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
PHASE1Completed
35 participants
Started: Jan 31, 2015 · Completed: Feb 18, 2019
Locations (1)
Headquarters
Seattle, WA, United States
Map
Loading map...